InflaRx to Participate in Guggenheim Securities 2nd Annual Healthcare Innovation Conference

JENA, Germany, Oct. 21, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm focused on developing anti-inflammatory treatments through the complement system, disclosed today its plan to attend the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. The specific arrangements are as follows:

Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Scheduled for November 10 – 12, 2025, in Boston, MA
A fireside chat is slated for November 11 at 2:30 PM ET

InflaRx will additionally host individual investor meetings on November 11. Access to a live stream and replay of the fireside chat can be found via a provided link .

Regarding InflaRx

InflaRx (Nasdaq: IFRX) operates as a biopharmaceutical enterprise at the forefront of anti-inflammatory treatments. It leverages its exclusive anti-C5a and anti-C5a receptor technologies to identify, advance, and market highly effective and targeted inhibitors of C5a—a complement activation factor—and its corresponding receptor. C5a serves as a potent inflammatory mediator implicated in the advancement of numerous inflammatory conditions. InflaRx has created vilobelimab, an innovative, intravenously administered, first-in-class anti-C5a monoclonal antibody. This antibody selectively attaches to free C5a and has exhibited disease-modifying clinical efficacy and good tolerability across several clinical trials. Furthermore, InflaRx is developing INF904, a small molecule inhibitor of C5a-induced signaling through the C5a receptor, administered orally.

Established in 2007, InflaRx maintains offices and subsidiaries in Jena and Munich, Germany, along with Ann Arbor, MI, USA. More information is available at www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) function as wholly owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).

Contact Information:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email:	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752

STATEMENTS REGARDING THE FUTURE

This press release includes statements that look to the future. Any declaration not rooted in historical fact constitutes a forward-looking statement, frequently identified by words like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. Such statements are present in various sections of this release and might encompass declarations concerning our aims, convictions, forecasts, perspectives, assessments, current projections, and the hazards, ambiguities, and additional considerations detailed under the sections titled “Risk factors” and “Cautionary statement regarding forward looking statements” in our regular SEC submissions. These declarations are valid only as of the date of this press release and entail both identified and unidentified risks, uncertainties, and other critical elements that could lead our actual outcomes, performance, or accomplishments to significantly diverge from any future results, performance, or achievements explicitly or implicitly suggested by these forward-looking statements. Considering these hazards, uncertainties, and other elements, readers should not unduly depend on these forward-looking statements. We disclaim any commitment to revise these forward-looking statements, even if new data emerges in the future, unless legally mandated.